Camurus
Develops long-acting medicines for patients with severe and chronic diseases
Highlights
- New on EvolcAdded 2026-11-01
About Camurus
Camurus develops pharmaceutical products using its FluidCrystal technology, a drug-delivery system designed for long-acting treatments. Its stated disease areas include central nervous system disorders, rare diseases, endocrinology, oncology and supportive care.
Its products include Buvidal, a prolonged-release buprenorphine injection, and Oczyesa, a prolonged-release octreotide injection. The company describes itself as a Swedish pharmaceutical company; the registered entity CAMURUS LTD is based in Duxford, United Kingdom, and was founded in 2017.
Product: Develops long-acting medicines and drug-delivery systems, including prolonged-release injectable treatments.
Jobs at Camurus
Leadership
- Fredrik Tiberg · President & CEOSource: company website
More biotech & pharma companies
Carus Animal Health
Animal health company developing point-of-care diagnostics and antibiotic alternatives for vets, farms and aquacultureNew on EvolcCauseway Sensors
Bioprocess sensor for at-line, real-time IgG quantification in bioreactor samples, for biopharma bioproduction teamsNew on EvolcCellcentric
Develops an oral cancer drug for people with multiple myeloma and other cancersNew on EvolcCellcraft
AI bioprocess control software and related tools for biomanufacturers and bioprocess teamsCentauri Therapeutics
Develops Alphamer immunotherapies for infectious diseases, including Gram-negative bacterial infections in high-risk patientsNew on EvolcCerevance
Develops cell-type-specific therapies and drug targets for patients with neurodegenerative, psychiatric and CNS disordersNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Privacy & consent
- CookiebotHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.